At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ABCL AbCellera Biologics
Trading 06-26 15:29:36 EDT
7.01
+0.35
+5.18%
High7.29Low6.47Vol10.54M
Open6.49D1 Closing6.66Amplitude12.30%
Mkt Cap2.14BTradable Cap1.42BTotal Shares305.26M
T/O73.68MT/O Rate5.20%Tradable Shares202.75M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

AbCellera Biologics call volume above normal and directionally bullish
TIPRANKS  ·  06-25 03:11
AbCellera Biologics call volume above normal and directionally bullish
Why AbCellera Biologics (ABCL) Is Up 5.5% After New Jazz T-Cell Engager Collaboration Agreement
Simply Wall St.  ·  06-20
Why AbCellera Biologics (ABCL) Is Up 5.5% After New Jazz T-Cell Engager Collaboration Agreement
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) and AbCellera Biologics (ABCL)
TIPRANKS  ·  06-18
Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Amylyx Pharmaceuticals Inc (AMLX) and AbCellera Biologics (ABCL)
Jazz Pharma, AbCellera ink antibody deal worth up to $876 million
Reuters  ·  06-17
Jazz Pharma, AbCellera ink antibody deal worth up to $876 million
Jazz Pharmaceuticals, AbCellera Ink $876 Million Cancer Treatment Pact
Dow Jones  ·  06-17
Jazz Pharmaceuticals, AbCellera Ink $876 Million Cancer Treatment Pact
Jazz Pharmaceuticals, AbCellera collaborate for TCE multispecific antibodies
TIPRANKS  ·  06-17
Jazz Pharmaceuticals, AbCellera collaborate for TCE multispecific antibodies
Jazz Pharmaceuticals, AbCellera team up on T-cell engaging multispecific antibodies for GI cancers
Reuters  ·  06-17
Jazz Pharmaceuticals, AbCellera team up on T-cell engaging multispecific antibodies for GI cancers
Jazz Pharmaceuticals and Abcellera Announce Collaboration to Discover Next-Generation T-Cell Engaging Multispecific Antibodies
THOMSON REUTERS  ·  06-17
Jazz Pharmaceuticals and Abcellera Announce Collaboration to Discover Next-Generation T-Cell Engaging Multispecific Antibodies
Abcellera Biologics - Collaboration Includes $56 Mln Upfront and up to $792 Mln Option Fees per Program
THOMSON REUTERS  ·  06-17
Abcellera Biologics - Collaboration Includes $56 Mln Upfront and up to $792 Mln Option Fees per Program
Abcellera Biologics - Jazz Has Exclusive Option to Develop and Commercialize Antibodies From Collaboration
THOMSON REUTERS  ·  06-17
Abcellera Biologics - Jazz Has Exclusive Option to Develop and Commercialize Antibodies From Collaboration
Is AbCellera (ABCL) Using Boardroom Oncology Talent to Redefine Its Clinical Ambitions?
Simply Wall St.  ·  06-13
Is AbCellera (ABCL) Using Boardroom Oncology Talent to Redefine Its Clinical Ambitions?
AbCellera shareholders elect John Montalbano, Stephen Quake as Class III directors
Reuters  ·  06-13
AbCellera shareholders elect John Montalbano, Stephen Quake as Class III directors
AbCellera files Form 3 for director Victor Sandor, reporting no beneficial ownership
Reuters  ·  06-12
AbCellera files Form 3 for director Victor Sandor, reporting no beneficial ownership
AbCellera Biologics Adds Victor Sandor to Board
TIPRANKS  ·  06-06
AbCellera Biologics Adds Victor Sandor to Board
AbCellera appoints Victor Sandor to board as independent director
Reuters  ·  06-05
AbCellera appoints Victor Sandor to board as independent director
Abcellera Appoints DR. Victor Sandor to Its Board of Directors
THOMSON REUTERS  ·  06-05
Abcellera Appoints DR. Victor Sandor to Its Board of Directors
Is AbCellera (ABCL) Turning Upgraded Earnings Forecasts Into a Durable Clinical-Stage Business Model?
Simply Wall St.  ·  06-04
Is AbCellera (ABCL) Turning Upgraded Earnings Forecasts Into a Durable Clinical-Stage Business Model?
A Look At AbCellera Biologics (ABCL) Valuation After Improved Earnings Outlook And Sector Outperformance
Simply Wall St.  ·  06-02
A Look At AbCellera Biologics (ABCL) Valuation After Improved Earnings Outlook And Sector Outperformance
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), AbCellera Biologics (ABCL) and Indivior (INDV)
TIPRANKS  ·  05-22
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), AbCellera Biologics (ABCL) and Indivior (INDV)
AbCellera publishes corporate overview on internal antibody pipeline, platform expansion strategy
Reuters  ·  05-20
AbCellera publishes corporate overview on internal antibody pipeline, platform expansion strategy

Introduction

Company Name.
AbCellera Biologics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Issue price:
--